NeuroPace Receives FDA Approval for ECoG Assistant, an AI-Driven Epilepsy Care Tool

NeuroPace (NASDAQ:NPCE) announced on May 29 that it received U.S. Food and Drug Administration approval for its ECoG Assistant tool, the first 'AI-driven clinician-enabled feature' designed to improve epilepsy care using long-term intracranial EEG data.

By Fatima Gulzar Sat, June 27, 2026 at 6:31 PM GMT+3 1 min read · Yahoo Finance · June 27, 2026, 15:31 UTC

Tickers: $NPCE

Topics: ai in healthcare epilepsy treatment neurotechnology

Read the full article at Yahoo Finance

More World news

Apple to Update HomeView Software Following Feedback on Voice Command Limitations The Verge · November 12, 2026, 16:53 UTC
Endeavour Mining Shares Drop Following Production Warning at Mana Gold Mine Seeking Alpha · November 12, 2026, 16:48 UTC
Stellantis CEO Warns of Multi-Billion Euro Impact from Chip Shortages and Raw Material Costs Seeking Alpha · November 12, 2026, 16:44 UTC
UBS Upgrades Rivian to Buy Rating Amid R2 Potential Motley Fool · November 12, 2026, 16:45 UTC
Stifel Downgrades EVgo to Hold Amid Weakening Growth Outlook Seeking Alpha · November 12, 2026, 16:41 UTC
Rowan Digital Infrastructure Secures Over $1.5 Billion in New Financing Seeking Alpha · November 12, 2026, 16:42 UTC
CAE Reports Q2 2027 Results with Increased EPS Guidance and Strong Defense Growth Motley Fool · November 12, 2026, 16:39 UTC
Alvotech Reports Q3 2026 Financial Results Amid Manufacturing Recovery Motley Fool · November 12, 2026, 16:39 UTC
Jacobs Solutions Declares Quarterly Dividend of $0.36 Per Share Seeking Alpha · November 12, 2026, 16:39 UTC
SOLV Energy Raises Revenue Guidance Following Record Q3 Project Execution Seeking Alpha · November 12, 2026, 16:40 UTC